Literature DB >> 7624155

Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.

L Liu1, N J Lassam, J M Slingerland, D Bailey, D Cole, R Jenkins, D Hogg.   

Abstract

The gene encoding the cell cycle inhibitor p16INK4A (also known as p16, MTS1, CDKN2 and INK4) has been mapped to human chromosome band 9p21, a region that also contains a putative melanoma susceptibility gene. Although germline mutations in the coding region of the p16INK4A gene have been detected in some families with inherited melanoma, many other families show no evidence of such mutations and hence the role of p16INK4A in the development of this tumor is still unclear. In this report, we describe a family with inherited melanoma in which a novel mutation in exon 2 of the p16INK4A gene segregates with the disease. The mutant gene encodes a protein with an in-frame deletion of two amino acids (Asp96 and Leu97). We show that the mutant protein is functionally abnormal: it is unable to bind cdk4 in vitro and does not inhibit colony formation in tertiary passage rat embryo fibroblasts. Moreover, in a metastatic lesion from one patient the wild type p16INK4A allele was deleted and the mutant allele retained. We conclude that family members carrying this germline mutation in the p16INK4A gene are predisposed to melanoma. By extension, these findings implicate the p16INK4A gene in the development of some cases of familial melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624155

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

3.  Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; P Arlauskas; W Du; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-06

4.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

Review 5.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

6.  p53 and p16INK4A mutations during the progression of glomus tumor.

Authors:  S Güran; E T Tali
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids.

Authors:  R S Nairn; S Kazianis; B B McEntire; L Della Coletta; R B Walter; D C Morizot
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 8.  Understanding the biology of melanoma and therapeutic implications.

Authors:  Ryan J Sullivan; David E Fisher
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

9.  Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.

Authors:  Farruk M Lutful Kabir; Patricia DeInnocentes; Allison Church Bird; R Curtis Bird
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-05-20       Impact factor: 2.416

Review 10.  Tumor Suppressor Inactivation in the Pathogenesis of Adult T-Cell Leukemia.

Authors:  Christophe Nicot
Journal:  J Oncol       Date:  2015-06-10       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.